IP Verse

Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5

EP2978451

ALEXION PHARMACEUTICALS, INC.
Application Number
EP14722916A
Filing Date
Mar 28, 2014
Status
Revoked
May 5, 2023
Grant Date
Nov 27, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2978451B1 was granted on Nov 27, 2019 by Alexion Pharmaceuticals, Inc. The patent is currently Revoked.

Oppositions Filed by other Companies on the Patent

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALNYLAM PHARMACEUTICALS, INC.Aug 27, 2020ADMISSIBLE
REGENERON PHARMACEUTICALS, INC.Aug 27, 2020ADMISSIBLE

More Opposed Patents of Alexion Pharmaceuticals, Inc.

The table below shows the patents of Alexion Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3167888Behandlung Von Patienten Mit Paroxysmaler Nachtlicher Hamoglobinurie Mit Einem KomplementinhibitorMay 1, 20241
EP2894165Methods And Compositions For Treating Complement-Associated DisordersJan 4, 20232
EP3207132Methods Of Shifting An Isoelectric Profile Of A Protein Product And Uses ThereofJul 31, 20191

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents